Relmada Therapeutics (RLMD) Short Interest Ratio & Short Volume $0.66 +0.05 (+7.87%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Relmada Therapeutics Short Interest DataRelmada Therapeutics (RLMD) has a short interest of 401,300 shares, representing 1.52% of the float (the number of shares available for trading by the public). This marks a -5.33% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 1.16 million shares to cover all short positions.Current Short Interest401,300 sharesPrevious Short Interest423,900 sharesChange Vs. Previous Month-5.33%Dollar Volume Sold Short$249.77 thousandShort Interest Ratio0.9 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares33,190,000 sharesShort Percent of Float1.52%Today's Trading Volume122,951 sharesAverage Trading Volume1,164,081 sharesToday's Volume Vs. Average11% Short Selling Relmada Therapeutics? Sign up to receive the latest short interest report for Relmada Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRLMD Short Interest Over TimeRLMD Days to Cover Over TimeRLMD Percentage of Float Shorted Over Time Relmada Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025401,300 shares $249.77 thousand -5.3%1.5%0.9 $0.62 7/15/2025423,900 shares $267.90 thousand -28.8%N/A0.2 $0.63 6/30/2025595,000 shares $357.18 thousand -14.5%2.3%0.3 $0.60 6/15/2025695,500 shares $486.99 thousand -38.5%2.6%0.4 $0.70 5/31/20251,130,000 shares $814.05 thousand -7.4%4.6%0.6 $0.72 5/15/20251,220,000 shares $504.35 thousand -39.9%4.9%0.7 $0.41 4/30/20252,030,000 shares $654.47 thousand +44.0%N/A1 $0.32 4/15/20251,410,000 shares $434.28 thousand -13.0%5.7%0.8 $0.31 3/31/20251,620,000 shares $437.40 thousand +8.7%6.5%1.7 $0.27 3/15/20251,490,000 shares $436.12 thousand +18.3%6.0%1.4 $0.29 Get the Latest News and Ratings for RLMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/20251,260,000 shares $327.60 thousand -28.0%5.1%0.8 $0.26 2/15/20251,750,000 shares $582.58 thousand +108.8%7.1%1.1 $0.33 1/31/2025838,000 shares $292.46 thousand -33.0%N/A0.6 $0.35 1/15/20251,250,000 shares $495.63 thousand -24.2%N/A1.3 $0.40 12/31/20241,650,000 shares $858 thousand -7.3%N/A1.7 $0.52 12/15/20241,780,000 shares $653.26 thousand +67.9%N/A2.3 $0.37 11/30/20241,060,000 shares $3.20 million -7.8%N/A1.6 $3.02 11/15/20241,150,000 shares $3.46 million -3.4%N/A6.1 $3.01 10/31/20241,190,000 shares $4.14 million -5.6%N/A6.7 $3.48 10/15/20241,260,000 shares $4.38 million +0.8%N/A6.9 $3.48 9/30/20241,250,000 shares $4.05 million +5.9%N/A6.6 $3.24 9/15/20241,180,000 shares $3.65 million -2.5%N/A6.6 $3.09 8/31/20241,210,000 shares $3.39 million -6.2%N/A10.8 $2.80 8/15/20241,290,000 shares $3.32 million -3.0%N/A11.5 $2.57 7/31/20241,330,000 shares $4.87 million -2.2%N/A12.2 $3.66 7/15/20241,360,000 shares $5.22 million +34.7%N/A13.1 $3.84 6/30/20241,010,000 shares $3.03 million -34.8%N/A9.6 $3.00 6/15/20241,550,000 shares $4.67 million +0.7%N/A14.9 $3.01 5/31/20241,540,000 shares $4.62 million -1.9%N/A11.1 $3.00 5/15/20241,570,000 shares $5.46 million -4.3%N/A10.6 $3.48 4/30/20241,640,000 shares $5.97 million -4.1%N/A9.4 $3.64 4/15/20241,710,000 shares $7.61 million +1.2%N/A8.1 $4.45 3/31/20241,690,000 shares $7.86 million -3.4%N/A7.4 $4.65 3/15/20241,750,000 shares $9.49 million No ChangeN/A5.4 $5.42 2/29/20241,750,000 shares $10.72 million +1.2%N/A5.5 $6.13 2/15/20241,730,000 shares $9.12 million +7.5%N/A5.6 $5.27 1/31/20241,610,000 shares $6.33 million +3.2%N/A5.6 $3.93 1/15/20241,560,000 shares $4.90 million +92.4%N/A6.3 $3.14 12/31/2023810,700 shares $3.36 million +26.9%N/A3.3 $4.14 12/15/2023638,800 shares $1.58 million -26.2%N/A3.7 $2.48The $7 company helping Nvidia build the world’s first trillion-dollar robot … (Ad)Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.Now he's identified his next potential winner. Click here to find out more. 11/30/2023865,800 shares $2.14 million -1.1%N/A5.3 $2.47 11/15/2023875,200 shares $2.65 million +10.1%N/A5.6 $3.03 10/31/2023794,700 shares $2.38 million +13.4%N/A5 $2.99 10/15/2023700,900 shares $2.17 million -2.5%N/A4.6 $3.10 9/30/2023718,700 shares $2.16 million +6.1%N/A4.9 $3.00 9/15/2023677,500 shares $2.09 million +9.7%N/A4.5 $3.09 8/31/2023617,700 shares $2.09 million -10.5%N/A3.8 $3.38 8/15/2023689,800 shares $2.35 million -18.8%N/A4.1 $3.41 7/31/2023849,900 shares $2.23 million -11.0%N/A4.8 $2.62 7/15/2023954,400 shares $2.71 million -9.1%N/A5 $2.84 6/30/20231,050,000 shares $2.58 million -46.7%N/A5.2 $2.46 6/15/20231,970,000 shares $5.02 million -5.3%N/A8.7 $2.55 5/31/20232,080,000 shares $5.91 million +16.9%N/A11.3 $2.84 5/15/20231,780,000 shares $5.50 million -3.3%N/A9.1 $3.09 4/30/20231,840,000 shares $4.64 million +0.6%N/A9.1 $2.52 4/15/20231,830,000 shares $4.96 million +4.0%N/A8.5 $2.71 3/31/20231,760,000 shares $3.98 million +13.6%N/A6.6 $2.26 3/15/20231,550,000 shares $3.97 million +6.2%N/A5 $2.56 2/28/20231,460,000 shares $5.26 million -8.8%N/A2.5 $3.60 2/15/20231,600,000 shares $5.94 million No ChangeN/A2.5 $3.71 1/31/20231,600,000 shares $6.50 million -20.4%N/A2.2 $4.06 1/15/20232,010,000 shares $8.28 million +12.3%N/A2.4 $4.12 12/30/20221,790,000 shares $6.25 million +4.1%N/A1.4 $3.49 12/15/20221,720,000 shares $5.40 million -13.6%N/A1.3 $3.14 11/30/20221,990,000 shares $9.25 million -28.2%N/A1.6 $4.65 11/15/20222,770,000 shares $16.32 million -4.2%N/A2.6 $5.89 10/31/20222,890,000 shares $18.47 million -13.7%N/A2.9 $6.39 10/15/20223,350,000 shares $20.77 million -26.2%N/A3.8 $6.20 9/30/20224,540,000 shares $168.07 million +25.1%N/A12.3 $37.02 9/15/20223,630,000 shares $124.84 million +11.7%N/A11.3 $34.39 8/31/20223,250,000 shares $94.71 million +3.2%N/A11.9 $29.14 8/15/20223,150,000 shares $91.79 million +1.0%N/A12.3 $29.14 7/31/20223,120,000 shares $79.87 million +1.0%N/A12.1 $25.60 7/15/20223,090,000 shares $69.43 million -4.9%N/A11.7 $22.47 6/30/20223,250,000 shares $61.72 million +21.7%N/A12 $18.99 6/15/20222,670,000 shares $44.59 million +1.1%N/A9.5 $16.70 5/31/20222,640,000 shares $49.61 million +21.1%N/A9.2 $18.79 5/15/20222,180,000 shares $43.16 million +32.9%N/A6.6 $19.80 4/30/20221,640,000 shares $41.18 million -4.7%N/A5.1 $25.11 4/15/20221,720,000 shares $44.77 million -4.4%N/A5.5 $26.03 3/31/20221,800,000 shares $48.58 million +23.3%N/A5.9 $26.99 3/15/20221,460,000 shares $32.49 million -11.0%N/A5.2 $22.25 2/28/20221,640,000 shares $33.64 million +34.4%N/A5.9 $20.51 2/15/20221,220,000 shares $24.40 million -8.3%N/A5.1 $20.00 1/31/20221,330,000 shares $24.46 million -21.3%N/A6.6 $18.39 1/15/20221,690,000 shares $33.56 million +24.3%10.7%10 $19.86 12/31/20211,360,000 shares $30.64 million +40.7%8.6%8.6 $22.53 12/15/2021966,900 shares $19.51 million +7.7%6.1%7.1 $20.18 11/30/2021897,600 shares $16.03 million +2.9%5.7%8.2 $17.86 11/15/2021872,400 shares $19.79 million -2.8%5.5%9.2 $22.69The $7 company helping Nvidia build the world’s first trillion-dollar robot … (Ad)Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.Now he's identified his next potential winner. Click here to find out more. 10/29/2021897,500 shares $21.06 million -5.9%5.7%8.2 $23.47 10/15/2021953,300 shares $22.53 million -4.3%6.1%4.1 $23.63 9/30/2021996,200 shares $26.11 million -2.3%6.3%4.1 $26.21 9/15/20211,020,000 shares $27.31 million -1.0%6.5%4.2 $26.77 8/31/20211,030,000 shares $24.63 million +12.1%6.6%4.4 $23.91 8/13/2021918,600 shares $20.99 million +30.5%5.9%3.9 $22.85 7/30/2021704,000 shares $18.30 million -11.9%4.3%3.1 $26.00 7/15/2021798,800 shares $25.20 million -11.7%4.9%8.1 $31.55 6/30/2021904,100 shares $28.94 million -6.5%5.5%10.1 $32.01 6/15/2021966,400 shares $30.92 million -6.2%5.9%11.3 $32.00 5/28/20211,030,000 shares $35.63 million +13.8%6.3%12.5 $34.59 5/14/2021904,800 shares $30.31 million +6.6%5.5%12.2 $33.50 4/30/2021849,000 shares $32.97 million -1.7%5.5%12.9 $38.83 4/15/2021863,500 shares $31.95 million +6.4%5.6%12 $37.00 3/31/2021811,600 shares $28.35 million +13.9%5.3%11.1 $34.93 3/15/2021712,800 shares $26.14 million -8.3%4.8%9.1 $36.67 2/26/2021777,600 shares $26.31 million -12.4%5.2%10 $33.84 2/12/2021887,200 shares $31.97 million -4.8%6.0%11.5 $36.03 1/29/2021931,800 shares $30.39 million -4.3%6.3%12.3 $32.61 1/15/2021974,000 shares $36.64 million +5.6%6.5%11.6 $37.62 12/31/2020922,000 shares $29.04 million +4.0%6.2%9.9 $31.50 12/15/2020886,600 shares $29.78 million -10.2%6.0%9.4 $33.59 11/30/2020987,300 shares $35.53 million -2.3%6.6%10.6 $35.99 11/15/20201,010,000 shares $32.90 million +1.1%6.8%10.9 $32.57 10/30/2020998,600 shares $31.12 million -18.8%6.8%10.9 $31.16 10/15/20201,230,000 shares $44.72 million -30.5%8.4%14.4 $36.36 RLMD Short Interest - Frequently Asked Questions What is Relmada Therapeutics' current short interest? Short interest is the volume of Relmada Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 401,300 shares of RLMD short. 1.52% of Relmada Therapeutics' shares are currently sold short. Learn More on Relmada Therapeutics' current short interest. What is a good short interest ratio for Relmada Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RLMD shares currently have a short interest ratio of 1.0. Learn More on Relmada Therapeutics's short interest ratio. What is a good short interest percentage for Relmada Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.52% of Relmada Therapeutics' floating shares are currently sold short. Is Relmada Therapeutics' short interest increasing or decreasing? Relmada Therapeutics saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 401,300 shares, a decline of 5.3% from the previous total of 423,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Relmada Therapeutics' short interest compare to its competitors? 1.52% of Relmada Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Relmada Therapeutics: CervoMed Inc. (12.92%), Milestone Pharmaceuticals Inc. (13.13%), ImmunoPrecise Antibodies Ltd. (1.81%), Celularity, Inc. (11.50%), Immix Biopharma, Inc. (1.18%), Cabaletta Bio, Inc. (13.39%), PMV Pharmaceuticals, Inc. (1.84%), MediciNova, Inc. (0.26%), Genenta Science S.p.A. Unsponsored ADR (0.05%), Ikena Oncology, Inc. (0.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Relmada Therapeutics stock? Short selling RLMD is an investing strategy that aims to generate trading profit from Relmada Therapeutics as its price is falling. RLMD shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Relmada Therapeutics? A short squeeze for Relmada Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RLMD, which in turn drives the price of the stock up even further. How often is Relmada Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RLMD, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies CervoMed Short Interest Milestone Pharmaceuticals Short Interest ImmunoPrecise Antibodies Short Interest Celularity Short Interest Immix Biopharma Short Interest Cabaletta Bio Short Interest PMV Pharmaceuticals Short Interest MediciNova Short Interest Genenta Science Short Interest Ikena Oncology Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RLMD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access